Drug Profile
Firtecan pegol - Belrose Pharma
Alternative Names: BEL-0222; EZN-2208; PEG-SN38; Pegylated-SN-38; SN38-PEGLatest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator Enzon Pharmaceuticals
- Developer Belrose Pharma; Enzon Pharmaceuticals; National Cancer Institute (USA)
- Class Antineoplastics; Camptothecins; Polyethylene glycols
- Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Colorectal cancer
- Phase I/II Neuroblastoma; Solid tumours
- Discontinued Lymphoma
Most Recent Events
- 16 Jan 2024 Firtecan pegol is still in phase II trials for Colorectal cancer in Canada, Israel, Netherlands, the US and UK (IV) (Enzon Pharmaceuticals pipeline, January 2024)
- 15 Jul 2013 Phase-I clinical trials in Solid tumours (combination therapy, metastatic disease) in USA (IV)
- 15 Jul 2013 Phase-I/II clinical trials in Neuroblastoma (monotherapy, in infants, children and adolescents, second-line therapy or greater) in USA (IV)